Pharmaceutical

FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well Tolerated

TORONTO, ON / ACCESSWIRE / September 18, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical…

12 months ago

TRIANA Biomedicines to Present at UBS Biotechnology Private Company Virtual Symposium

LEXINGTON, MA / ACCESSWIRE / September 18, 2023 / TRIANA Biomedicines, Inc. (TRIANA), an innovative biopharmaceutical company focused on advancing…

12 months ago

LAPIX Therapeutics Inc. Announces FDA Clearance of IND Application for its Treg-expanding Tim3/4 Agonist LPX-TI641 to Treat Multiple Sclerosis

BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- LAPIX Therapeutics, Inc. (“LAPIX”), a biopharmaceutical company focused on developing novel, orally bioavailable…

12 months ago

Harvard Bioscience and Etisense Announce Agreement for Supply and Distribution of DECRO Miniature Telemetry Jacket Platform for Pre-Clinical Research

Includes dedicated version for integration with Ponemah data management software from Data Sciences International (DSI) Expands reach of unique, non-invasive…

12 months ago

Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company

AI-powered target discovery for a bacterial pathogen with a high medical need where no vaccine is currently available Evaxion’s proprietary AI-platforms…

12 months ago

Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference

CORAL GABLES, Fla., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused…

12 months ago

Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer

Research will use Myriad’s high-definition MRD testing platform based on whole-genome sequencingSALT LAKE CITY, Sept. 18, 2023 (GLOBE NEWSWIRE) --…

12 months ago

TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned

Full ENVASARC accrual expected in Q4 and final data expected in mid-2024SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- TRACON…

12 months ago

Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs

- Seasoned biopharma medical leader joins Apnimed as it initiates its Phase 3 clinical program for AD109, a potential new…

12 months ago

Ambrx to Participate in the Cantor Fitzgerald Global Healthcare Conference

Morgan Stanley Fireside Chat Replay Now AvailableSAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the…

12 months ago